摘要
2009年甲型H1N1流感病毒暴发流行以来,各国均开展了甲型H1N1流感疫苗免疫接种工作。本文通过探讨美国政府针对免疫接种后疫苗安全性监测所采取的措施,比较我国与美国在疫苗不良事件监测工作中存在的差距,为我国药物警戒工作的深入发展提供借鉴。
Vaccination campaigns were initiated in many countries after 2009 H1N1 influenza pandemic had occurred. This article will discuss the activities of safety monitoring after immunization at the level of US governments, to compare the difference between the US and China in adverse events monitoring and provide reference for the profound development of China pharmacovigilance.
出处
《中国药物警戒》
2011年第12期725-728,共4页
Chinese Journal of Pharmacovigilance
